Cogent Biosciences (COGT) EBIT (2017 - 2020)
Historic EBIT for Cogent Biosciences (COGT) over the last 4 years, with Q4 2020 value amounting to -$11.5 million.
- Cogent Biosciences' EBIT fell 61142.86% to -$11.5 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$82.2 million, marking a year-over-year decrease of 15545.09%. This contributed to the annual value of -$333.4 million for FY2025, which is N/A changed from last year.
- Latest data reveals that Cogent Biosciences reported EBIT of -$11.5 million as of Q4 2020, which was down 61142.86% from -$57.2 million recorded in Q3 2020.
- Cogent Biosciences' 5-year EBIT high stood at $2.2 million for Q4 2019, and its period low was -$57.2 million during Q3 2020.
- Over the past 4 years, Cogent Biosciences' median EBIT value was -$8.2 million (recorded in 2018), while the average stood at -$11.0 million.
- Per our database at Business Quant, Cogent Biosciences' EBIT surged by 12487.78% in 2019 and then plummeted by 61142.86% in 2020.
- Cogent Biosciences' EBIT (Quarter) stood at -$6.9 million in 2017, then tumbled by 30.87% to -$9.0 million in 2018, then skyrocketed by 124.88% to $2.2 million in 2019, then crashed by 611.43% to -$11.5 million in 2020.
- Its last three reported values are -$11.5 million in Q4 2020, -$57.2 million for Q3 2020, and -$7.4 million during Q2 2020.